Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
暂无分享,去创建一个
J. Bruix | J. Llovet | A. Forner | C. Ayuso | M. Brunet | M. Varela | M. Real | M. Burrel | M. Sala | L. Castells | X. Montañá
[1] H. Ohishi,et al. Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellular carcinoma , 1990, CardioVascular and Interventional Radiology.
[2] Donald L. Miller,et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. , 2006, Journal of vascular and interventional radiology : JVIR.
[3] A. Lloyd,et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. , 2006, Journal of vascular and interventional radiology : JVIR.
[4] C. Georgiades,et al. Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. , 2005, Journal of vascular and interventional radiology : JVIR.
[5] J. Bruix,et al. Management of hepatocellular carcinoma , 2005, Hepatology.
[6] Josepa Ribes,et al. Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.
[7] J. Bruix,et al. Chemoembolization for hepatocellular carcinoma. , 2004, Gastroenterology.
[8] R. Guillevin,et al. In vitro study of the compatibility of tris-acryl gelatin microspheres with various chemotherapeutic agents. , 2003, Journal of vascular and interventional radiology : JVIR.
[9] J. Bruix,et al. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.
[10] D. Ball,et al. In vitro stability of tris-acryl gelatin microspheres in a multipharmaceutical chemoembolization solution. , 2003, Journal of vascular and interventional radiology : JVIR.
[11] M. Choti,et al. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. , 2002, Journal of vascular and interventional radiology : JVIR.
[12] Ramon Planas,et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.
[13] John Wong,et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.
[14] O. Matsui,et al. Accumulation of Iodized Oil Within the Non-Neoplastic Liver Adjacent to Hepatocellular Carcinoma via the Drainage Routes of the Tumor After Transcatheter Arterial Embolization , 2001, CardioVascular and Interventional Radiology.
[15] Jacques Ferlay,et al. Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.
[16] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.
[17] M. Soulen,et al. Risk factors for liver abscess formation after hepatic chemoembolization. , 2001, Journal of vascular and interventional radiology : JVIR.
[18] W. M. Lam,et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. , 2000, Journal of hepatology.
[19] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[20] J. Verweij,et al. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. , 1999, Analytical Biochemistry.
[21] O. Ernst,et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. , 1999, AJR. American journal of roentgenology.
[22] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.
[23] M. Kusano,et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. , 1997, Seminars in oncology.
[24] T. de Baère,et al. Liver abscess formation after local treatment of liver tumors , 1996, Hepatology.
[25] R. Yamada,et al. [Alginate gel beads for chemoembolization: initial report]. , 1995, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica.
[26] J. Bruix,et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. , 1995, Journal of hepatology.
[27] N. Dobbs,et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. , 1991, Journal of hepatology.
[28] P. Johnson,et al. Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. , 1990, Journal of hepatology.
[29] J. Barbare,et al. Hepatic extraction of adriamycin in patients with hepatocellular carcinoma. , 1984, European journal of cancer & clinical oncology.